Sinthesis of benzopyrimidin-4-one and 3-H substituted derivatives based on them
Authors
Elmuradov Burkhon Juraevich, Zulpanov Fazliddin Abduxakimovich, Arzanov Ravshan Xurramovich, Zakhidova Aziza Bakhromovna
Share
Annotation
As a result of studying the synthesis and biological activity of condensed
heterocyclic compounds, new drugs have been developed, including derivatives of 3-alkylquinazolin-4-one, and their bioactive derivatives have been identified. The development of new drugs based on them is relevant.
Keywords
Authors
Elmuradov Burkhon Juraevich, Zulpanov Fazliddin Abduxakimovich, Arzanov Ravshan Xurramovich, Zakhidova Aziza Bakhromovna
Share
References:
Xiaoqing Wu, Mingdong Li, Wenhua Tang, Youguang Zheng, Jiqin Lian, Liang Xu, Min Ji. Design synthesis and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives. Chemical biology & drug design. 2011;78(6):932-940 p. https://doi.org/10.1111/j.1747-0285.2011.01234.x
Kalpana Singh, P.P. Sharma, A. Kumar, Anurag Chaudhary and R.K. Roy. 4-Aminoquinazoline Analogs: A Novel Class of Anticancer Agents. Mini-Reviews in Medicinal Chemistry. olume 13, Issue 8, 2013 Page: [1177 - 1194]. DOI: 10.2174/1389557511313080006
Giovanni Marzaro, (PhD), Adriano Guiotto, Adriana Chilin. Quinazoline derivatives as potential anticancer agents: a patent review (2007 – 2010). Expert Opinion on Therapeutic Patents, 22(3), 223–252. https://doi.org/10.1517/13543776.2012.665876
Mikra, C.; Bairaktari, M.; Petridi, M.-T.; Detsi, A.; Fylaktakidou, K.C. Green Process for the Synthesis of 3-Amino-2-methyl-quinazolin- 4(3H)-one Synthones and Amides Thereof:DNA Photo-Disruptive and Molecular Docking Studies. Processes 2022, 10, 384. https://doi.org/10.3390/pr10020384
Shi-Ben Wang, Xian-Qing Deng, Yan Zheng, Yan-Ping Yuan, Zhe-Shan Quan, Li-Ping Guan. Synthesis and evaluation of anticonvulsant and antidepressant activities of 5-alkoxytetrazolo[1,5-c]thieno[2,3-e]pyrimidine derivatives. European Journal of Medicinal Chemistry Volume 56, October 2012, Pages 139-144. https://doi.org/10.1016/j.ejmech.2012.08.027
Raffaella Sordella, Daphne W. Bell, Daniel A. Haber, Jeffrey Settleman. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Europe PMC. 20 Aug 2004. Vol 305, Issue 5687 pp. 1163-1167. DOI: 10.1126/science.1101637
Martin H. Cohen, John R. Johnson, Yeh-Fong Chen, Rajeshwari Sridhara, Richard Pazdur. FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets. The Oncologist, Volume 10, Issue 7, August 2005, Pages 461–466, https://doi.org/10.1634/theoncologist.10-7-461
Pawan K., Premnath D., Muhammad T., Mazlee S., Yaman M., Nurul S., Muhammad S. et al. A controlled, efficient and robust process for the synthesis of an epidermal growth factor receptor inhibitor: Afatinib Dimaleate. February 4, 2019. 5-105-106 p. DOI:10.25082/CR.2019.01.001
Xiaoqing Wu, Mingdong Li, Yang Qu, Wenhua Tang, Youguang Zheng, Jiqin Lian, Min Ji, Liang Xu. Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg Med Chem. 2010 Apr 21;18(11):3812–3822. doi: 10.1016/j.bmc.2010.04.046
Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara; Gang Chen, W. David McGuinn, Jr., David Morse Sophia Abraham, Atiqur Rahman, Chenyi Liang, Richard Lostritto, Amy Baird, Richard Pazdur. RFDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist; 8: (2004) 303–306 p. https://doi.org/10.1158/1078-0432.CCR-03-0564
12.Elmuradov B.Zh., Yakubov U.M., Zhurayev B.B., Tadjimukhamedov K.S., Zakhidov K.A. Selective Bromination of Tricyclik Quinazolines // World wide journal of multidisciplinary research and development.- 2017. -3(10).- P. 1-5.
Other articles of the issue
